Alexion Pharmaceuticals, Inc. company logo

# RNN 1st Gen Model Alexion Pharmaceuticals, Inc. Pharmaceutical preparations

Prediction models:
68.33% successful of 60 deals
$ 121.94 Last close price
at 12-oct-2018

ALXN

Model's trade recommendations 1.53% Return for period

-4.65% Annual return

$25.42B Market Cap

β 1.11  

ALXN

Model (following trade recommendations)

ALXN

Underlying stock

S&P 500

Index
Return for period 1.53%
3.51%
1.78%
52wk return -17.04%
-13.28%
16.82%
52wk Range
106.04—143.16
2000.54—2399.63
Sortino ratio 0.01
Sharpe ratio 0.01
Norm. RMSE 1.46%
Downside risk 21.52%
Volatility 0.00%
  • STRONG BUY Analysts consensus recommendation

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Alexion Pharmaceuticals, Inc. (ALXN) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for ALXN model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 213M
P/E 21.16
Shares Outstanding 223M
% Held by Insiders 4.35%
% Held by Institutions 95.89%
EPS (last reported FY) $5.16
EPS (last reported Q) $1.53
EPS, estimated (last reported Q) $1.29
Total revenues $4 B
Net income $0 B